Oncology News | pharmaphorum

News

MSD splits pharma business, hiving off oncology

MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.

News

FDA clears first all-oral combo for first-line CLL treatment

AstraZeneca's Calquence and AbbVie/Roche's Venclexta have become the first all-oral, fixed-duration regimen for newly-diagnosed CLL.

News

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Gilead has shored up its position in cell therapies with a deal to acquire Arcellx, taking full control of their partnered multiple myeloma CAR-T.

News

Elderly man talks to younger female nurse beside a Grail screening vehicle

Grail's multi-cancer test fluffs its lines in UK trial

Grail's Galleri blood test for cancer screening missed the mark in the much-anticipated NHS-Galleri trial, wreaking havoc with the firm's share price.

News

Ex-Novartis CMO John Tsai joins Daiichi Sankyo

Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, who is stepping down after five years in the role.

News

Scrabble lettering of Two and One on grass

Makary says FDA will "end two-trial dogma" for approvals

The FDA plans to adopt a new policy that will do away with the default requirement to base regulatory filings for new medicines on two pivotal trials.

MSD splits pharma business, hiving off oncology

FDA clears first all-oral combo for first-line CLL treatment

Gilead buys cell therapy partner Arcellx for up to $7.8bn

Grail's multi-cancer test fluffs its lines in UK trial

Ex-Novartis CMO John Tsai joins Daiichi Sankyo

Makary says FDA will "end two-trial dogma" for approvals

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks